Northwestern University researchers report that a small structural change in a therapeutic HPV cancer vaccine sharply increased anti-tumor immune activity in preclinical testing, even though the ingredients stayed the same.
The work focuses on how arranging vaccine components—especially the orientation and placement of a cancer-targeting peptide—can influence how strongly the immune system attacks HPV-driven tumors.
Tiny change, bigger immune response
In the study, scientists built a therapeutic vaccine using a spherical nucleic acid (SNA), a globular DNA-based structure that naturally enters and stimulates immune cells. They deliberately rearranged components within the SNA and tested multiple configurations in humanized animal models of HPV-positive cancer and in patient-derived head and neck cancer tumor samples.
One specific design outperformed the others by shrinking tumors, extending survival in animal models, and generating larger numbers of highly active cancer-killing T cells, according to the reports. The research was published in Science Advances on Feb. 11, and the team describes the result as a clear example of how nanoscale architecture can determine whether a nanovaccine produces a modest response or a potent, tumor-destroying one.
What the vaccine targets
The researchers aimed their approach at cancers caused by human papillomavirus (HPV), noting that HPV causes most cervical cancers and a rapidly growing portion of head and neck cancers. The reports emphasize that existing HPV vaccines can prevent infection but do not help patients fight cancer after it has already developed.
To address that gap, the team designed therapeutic vaccines intended to train CD8 “killer” T cells to recognize and destroy HPV-positive cancer cells. Each vaccine particle contained a nanoscale lipid core, immune-activating DNA, and a short fragment of an HPV protein already present in tumor cells.
Why structure mattered more than new ingredients
All tested versions of the vaccine used the same ingredients, and the only change was how the HPV-derived peptide fragment (the antigen) was positioned and oriented. The team tested three designs: one that placed the peptide inside the nanoparticle and two that displayed it on the surface, with the surface versions differing by whether the peptide was attached via its N-terminus or C-terminus.
The version that displayed the antigen on the particle’s surface and attached it via its N-terminus produced the strongest immune response in the reported experiments. In those tests, the killer T cells produced up to eight times more interferon-gamma, described as a key anti-tumor signal. The same design also showed stronger cancer cell killing in patient tumor samples—reported as a two- to threefold increase—and significantly slowed tumor growth in humanized mouse models.
Jochen Lorch said the improvement did not require new ingredients or a higher dose, stating, “It came from presenting the same components in a smarter way.” He also described the immune system as “sensitive to the geometry of molecules,” and said optimizing how the antigen is attached helped immune cells process it more efficiently.
“Structural nanomedicine” and what comes next
Chad A. Mirkin, who led the study with Lorch, connects the findings to an emerging field he coined as “structural nanomedicine,” which is defined by SNAs that he invented. Mirkin argued that the approach is about identifying configurations that maximize efficacy while minimizing toxicity, saying, “we can build better medicines from the bottom up.”
The reports contrast this strategy with conventional vaccine development that often mixes antigens and adjuvants together without structural control, which Mirkin calls the “blender approach.” Mirkin also said vaccine and drug development has shifted toward more complex but less structured medicines, adding that “to create the most effective cancer vaccines, we will have to” do better than particles with inconsistent structure.
The Northwestern team has applied the structural nanomedicine approach to SNA vaccines for several cancers—including melanoma, triple-negative breast cancer, colon cancer, prostate cancer, and Merkel cell carcinoma—reporting promise in preclinical models. The same materials say seven SNA drugs have already entered human clinical trials for a range of diseases, and that SNAs are part of more than 1,000 commercial products.
Looking ahead, Mirkin said he wants to revisit vaccine candidates that seemed promising but did not produce strong enough immune responses, using nanoscale architecture as a blueprint to improve performance with known components. The reports also note Mirkin’s view that artificial intelligence and machine learning could help search through many possible structural combinations to identify the most effective arrangements.
The study was supported by the National Cancer Institute, the Lefkofsky Family Foundation, and the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, according to Northwestern’s materials.
